## IN THE CLAIMS:

Claims 1-9, 11, 19, 20 and 23 through 30 have been canceled. Claims 10, 14, 17, 18, 21, and 22 have been amended herein. New claim 31 is to be added. All of the pending claims 10, 12 through 18, 21, 22, and 31 are presented herein, and currently under examination. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

## **Listing of Claims:**

- 1. through 9. (Canceled).
- 10. (Currently amended) A method for obtaining an infectious recombinant <u>very virulent</u> Infectious Bursal Disease Virus (rIBDV) (vvIBDV) incapable of growing on a non-bursa cell derived cell, said method comprising:

transfecting at least one first cell, which cell is non-permissive for vvIBDV, with a nucleic acid comprising an IBDV a vvIBDV genome at least partly derived from IBDV;

incubating said at least one first cell in a culture medium;

recovering rIBDV vvIBDV from said at least one transfected first cell or said culture medium; and

propagating said recovered <u>rIBDV</u> <u>vvIBDV</u> in at least one second cell which is permissive for said <u>rIBDV</u> <u>vvIBDV</u>.

- 11. (Canceled).
- 12. (Previously Presented) The method according to claim 10 wherein said at least one first cell is a non-bursa cell-derived cell.
- 13. (Previously Presented) The method according to claim 12 wherein said at least one second cell is a bursa cell-derived cell.

- 14. (Currently Amended) The method according to claim 13 12 wherein said at least one first cell, such as is a CEF cell, a VERO cell or a QM5 cell, is non-permissive for vvIBDV.
- 15. (Previously Presented) The method according to claim 14 wherein said at least one first cell has additionally been provided with a helper virus or a viral protein derived from a helper virus.
- 16. (Previously Presented) The method according to claim 15 wherein said viral protein comprises T7-polymerase.
- 17. (Currently amended) The method according to claim 16 wherein said <del>rIBDV</del> vvIBDV has at least retained the incapacity to <del>substantially</del> be propagated on a vvIBDV non-permissive cell selected from the group consisting of a VERO, a QM5 and a CEF cell.
- 18. (Currently Amended) The method according to claim 17 13 wherein said at least one permissive-second cell is a primary bursa cell.
  - 19. (Canceled).
  - 20. (Canceled).
- 21. (Currently Amended) The method according to claim 20 10 wherein said rIBDV vvIBDV comprises at least a nucleic acid derived from a serotype II IBDV nucleic acid.
- 22. (Currently amended) The method according to claim 21 wherein said <del>rIBDV</del> vvIBDV is lacking at least one immunodominant epitope specific for a serotype I IBDV.
  - 23. through 30. (Canceled).
- 31. (New) The method according to claim 10 wherein said at least one second cell is a bursa cell-derived cell.